Evidence map›Paper›PMID 23871513›Full record

ArticleJACC. Cardiovascular interventions2013

Detection by near-infrared spectroscopy of large lipid core plaques at culprit sites in patients with acute ST-segment elevation myocardial infarction.

Ryan D Madder, James A Goldstein, Sean P Madden, Rishi Puri, Kathy Wolski, Michael Hendricks, Stephen T Sum, Annapoorna Kini, Samin Sharma, David Rizik and 10 more

3 registry-linked trialsAbstract read
PubMed Publisher
In one paragraph

Article in JACC. Cardiovascular interventions, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
21.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03067844 phase3completedstarted 2017, after this paper: background citation

Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study

Ran2017Enrolled294Registered outcomes16Posted comparisons0ConditionsAtheroma; Myocardial, Coronary Circulation, Coronary VesselArmsAlirocumab
Open the trial in the graph
NCT04719221 phase4unknown statusstarted 2021, after this paper: background citation

A Single-center, Randomized, Parallel-group, Open-label Pilot Study to Evaluate the Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome

Ran2021Enrolled60Registered outcomes8Posted comparisons0ConditionsAcute Coronary Syndrome, Clinical TrialArmsEvolocumab, NIRS IVUS
Open the trial in the graph
NCT02350959 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

Evaluation of Adverse Plaque Characteristics in Coronary Computed Tomography Angiography Using Combined Near Infrared Spectroscopy With Intravascular Ultrasound [CITRUS Study]

TypeinterventionalSponsorNational Health Insurance Service Ilsan HospitalRan2015 to 2017Enrolled100ConditionsPlaqueArmsAtorvastatin
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 196 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Visualization of Vulnerable Coronary Plaque and Prevention of Plaque Rupture.Juntendo Iji zasshi = Juntendo medical journal · 2024
    Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 12 institutions in 2 countries.

Ryan D MadderFrederik Meijer Heart and Vascular Institute, Spectrum Health, Grand Rapids, Michigan 49503, USA. ryan.madder@spectrumhealth.org
James A Goldstein
Sean P Madden
Rishi Puri
Kathy Wolski
Michael Hendricks
Stephen T Sum
Annapoorna Kini
Samin Sharma
David Rizik
Emmanouil S Brilakis
Kendrick A Shunk
John Petersen
Giora Weisz
Renu Virmani
Stephen J Nicholls
Akiko Maehara
Gary S Mintz
Gregg W Stone
James E Muller
Infrared Laboratories (United States) · USNewYork–Presbyterian Hospital · USCleveland Clinic · USMount Sinai Hospital · USBotsford Hospital · USCVPath Institute · USSan Francisco VA Medical Center · USScottsdale Community College · USSouth Australian Health and Medical Research Institute · AUSpectrum Health · USSwedish Medical Center · USVA North Texas Health Care System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study sought to describe near-infrared spectroscopy (NIRS) findings of culprit lesions in ST-segment elevation myocardial infarction (STEMI).

backgroundAlthough autopsy studies demonstrate that most STEMI are caused by rupture of pre-existing lipid core plaque (LCP), it has not been possible to identify LCP in vivo. A novel intracoronary NIRS catheter has made it possible to detect LCP in patients.

methodsWe performed NIRS within the culprit vessels of 20 patients with acute STEMI and compared the STEMI culprit findings to findings in nonculprit segments of the artery and to findings in autopsy control segments. Culprit and control segments were analyzed for the maximum lipid core burden index in a 4-mm length of artery (maxLCBI(4mm)).

resultsMaxLCBI(4mm) was 5.8-fold higher in STEMI culprit segments than in 87 nonculprit segments of the STEMI culprit vessel (median [interquartile range (IQR)]: 523 [445 to 821] vs. 90 [6 to 265]; p < 0.001) and 87-fold higher than in 279 coronary autopsy segments free of large LCP by histology (median [IQR]: 523 [445 to 821] vs. 6 [0 to 88]; p < 0.001).Within the STEMI culprit artery, NIRS accurately distinguished culprit from nonculprit segments (receiver-operating characteristic analysis area under the curve = 0.90). A threshold of maxLCBI(4mm) >400 distinguished STEMI culprit segments from specimens free of large LCP by histology (sensitivity: 85%, specificity: 98%).

conclusionsThe present study has demonstrated in vivo that a maxLCBI(4mm) >400, as detected by NIRS, is a signature of plaques causing STEMI.

Indexed as

Plaque, AtheroscleroticSpectroscopy, Near-InfraredArea Under CurveCase-Control StudiesCoronary AngiographyCoronary Artery DiseaseCoronary VesselsHumansLipidsLogistic ModelsMyocardial InfarctionPercutaneous Coronary InterventionPredictive Value of TestsPrognosisROC CurveRupture, SpontaneousLipidsarea under the curveAUCinterquartile rangeintravascular ultrasoundIQRIVUSLCBILCPlipid core burden indexlipid core plaquemaximum lipid core burden index in 4 mmMaxLCBI(4mm)myocardial infarctionnear-infrared spectroscopyNIRSPBPCIpercutaneous coronary interventionplaque burdenSTEMIST-segment elevation myocardial infarctionThrombolysis In Myocardial InfarctionTIMIvulnerable plaque

Identifiers

PMID23871513
OpenAlexW2009358044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.